| Current Price | $126.78 | Mkt Cap | $22.9B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 199.55 |
| Prev. Close | $126.78 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.00 - $0.00 | Volume | 1,091,934 |
| 52-Wk Range | $62.88 - $128.77 | Avg. Daily Vol. | 1,742,539 |
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
| Current Price | $126.78 | Mkt Cap | $22.9B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 199.55 |
| Prev. Close | $126.78 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.00 - $0.00 | Volume | 1,091,934 |
| 52-Wk Range | $62.88 - $128.77 | Avg. Daily Vol. | 1,742,539 |
The best Bull and Bear pitches based on recency and number of recommendations.
The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per… More
Read the most recent pitches from players about BMRN.
Recs
tomfoolme
(50.65)
Submitted: 6/21/2020 12:17:00 AM :
Start Price:
$122.38
NASDAQ:BMRN Score:
+2.35
fool article and rec +25% in month
Recs
mrbill6
(21.41)
Submitted: 6/20/2020 10:35:24 PM :
Start Price:
$122.38
NASDAQ:BMRN Score:
+2.35
Performance
Recs
TMFAdriaCimino
(55.60)
Submitted: 6/5/2020 4:24:13 AM :
Start Price:
$109.94
NASDAQ:BMRN Score:
+17.09
The catalysts ahead: An upcoming FDA decision on valoctocogene roxaparvovec would be the first approval for gene therapy for hemophilia. Also, the company expects to be profitable for the first time on a GAAP basis this year.
Find the members with the highest scoring picks in BMRN.
GlobalTraveler (78.51) Score: +801.69
The Score Leader is the player with the highest score across all their picks in BMRN.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| GlobalTraveler | 78.51 |
|
|
3Y | $10.04 | +1,162.75% | +361.06% | +801.69 | 0 Comment | |
| kaywonder | < 20 |
|
|
5Y | $10.11 | +1,154.01% | +364.21% | +789.79 | 0 Comment | |
| vacafun4 | 91.36 | 3/6/2009 |
|
3Y | $10.18 | +1,145.38% | +364.55% | +780.83 | 0 Comment | |
| BreakerBeth | 95.57 | 5/17/2006 |
|
5Y | $12.26 | +934.09% | +159.79% | +774.30 | 1 Comment | |
| makednoc | < 20 |
|
|
3Y | $10.29 | +1,132.07% | +359.93% | +772.14 | 0 Comment | |
| RBBioContest06 | 73.02 | 6/1/2006 |
|
1Y | $13.05 | +871.49% | +162.08% | +709.41 | 1 Comment | |
| geolitjon | < 20 | 4/6/2009 |
|
5Y | $12.00 | +956.50% | +277.89% | +678.61 | 0 Comment | |
|
luke4489 | < 20 | 2/23/2009 |
|
NS | $11.80 | +974.41% | +305.44% | +668.97 | 0 Comment |
| jacobcyh | 63.60 | 4/9/2009 |
|
5Y | $12.45 | +918.31% | +272.12% | +646.19 | 0 Comment | |
| GoLions1989 | < 20 | 4/9/2009 |
|
1Y | $12.45 | +918.31% | +272.12% | +646.19 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
